GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
-6.77%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$287M
AUM Growth
+$287M
(-7.6%)
Cap. Flow
-$57.4M
Cap. Flow
% of AUM
-19.96%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
78
New
11
Increased
22
Reduced
19
Closed
17
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$11.8M |
| 2 |
Biohaven
BHVN
|
$7.12M |
| 3 |
Rezolute
RZLT
|
$6.11M |
| 4 |
CG Oncology
CGON
|
$5.84M |
| 5 |
Corbus Pharmaceuticals
CRBP
|
$5.34M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$11.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$9.11M |
| 3 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$6.65M |
| 4 |
TG Therapeutics
TGTX
|
$5.78M |
| 5 |
Insmed
INSM
|
$5.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Insmed
INSM
$30.3B
| $4.36M | 1.36% |
65,000
-85,000
| -57% | -$5.7M |
|
|
BPMC
27
DELISTED
Blueprint Medicines
BPMC
| $4.31M | 1.35% |
40,000
-32,761
| -45% | -$3.53M |
|
28
Savara
SVRA
$591M
| $4.24M | 1.33% |
1,050,876
-549,124
| -34% | -$2.21M |
|
29
Tenaya Therapeutics
TNYA
$192M
| $4.19M | 1.31% |
1,350,000
+575,000
| +74% | +$1.78M |
|
30
Replimune Group
REPL
$460M
| $4.05M | 1.27% |
450,000
-200,000
| -31% | -$1.8M |
|
31
enGene Holdings
ENGN
$249M
| $3.96M | 1.24% |
420,331
+220,331
| +110% | +$2.08M |
|
32
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.66M | 1.14% |
225,000
| – | – |
|
33
BridgeBio Pharma
BBIO
$9.91B
| $3.55M | 1.11% |
140,000
-35,000
| -20% | -$887K |
|
34
Korro Bio
KRRO
$245M
| $3.39M | 1.06% |
+100,000
| New | +$3.39M |
|
35
Nuvation Bio
NUVB
$1.08B
| $3.36M | 1.05% |
+1,150,000
| New | +$3.36M |
|
|
BBOT
36
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $3.07M | 0.96% |
300,000
| – | – |
|
37
Taysha Gene Therapies
TSHA
$791M
| $2.8M | 0.88% |
1,250,000
+300,000
| +32% | +$672K |
|
38
Cabaletta Bio
CABA
$144M
| $2.77M | 0.87% |
370,899
-4,101
| -1% | -$30.7K |
|
39
Neurogene
NGNE
$284M
| $2.55M | 0.8% |
70,000
+45,000
| +180% | +$1.64M |
|
40
Janux Therapeutics
JANX
$1.38B
| $2.09M | 0.66% |
+50,000
| New | +$2.09M |
|
41
Arvinas
ARVN
$580M
| $2M | 0.63% |
75,000
+35,000
| +88% | +$932K |
|
42
Regenxbio
RGNX
$498M
| $1.99M | 0.62% |
170,000
+50,000
| +42% | +$585K |
|
43
Cytokinetics
CYTK
$5.98B
| $1.8M | 0.56% |
33,200
+13,200
| +66% | +$715K |
|
|
ELEV
44
DELISTED
Elevation Oncology
ELEV
| $1.62M | 0.51% |
600,000
+350,000
| +140% | +$945K |
|
45
Krystal Biotech
KRYS
$4.35B
| $1.56M | 0.49% |
8,500
-5,500
| -39% | -$1.01M |
|
46
Annexon
ANNX
$225M
| $1.52M | 0.48% |
+310,000
| New | +$1.52M |
|
47
ProQR Therapeutics
PRQR
$256M
| $1.49M | 0.47% |
+900,000
| New | +$1.49M |
|
|
ATYR
48
aTyr Pharma
ATYR
$560M
| $1.25M | 0.39% |
800,000
+200,000
| +33% | +$312K |
|
49
Wave Life Sciences
WVE
$1.27B
| $998K | 0.31% |
+200,000
| New | +$998K |
|
50
Arrowhead Research
ARWR
$3.84B
| $910K | 0.28% |
35,000
| – | – |
|